Fox Chase Researchers Connect Multifocal/Multicentric Breast Cancer to a Patient's Increased Risk of Local Recurrence
BOSTON, MA (October 28, 2012)—Not all women diagnosed with operable breast cancer present with a single tumor; some have multifocal disease appear in the breast, which means multiple tumors found in the same breast quadrant, while others have multicentric disease, where multiple tumors are found in separate breast quadrants. Multifocal or multicentric disease is not a standard indication to receive radiation after mastectomy. For patients who undergo lumpectomy, radiation dose and extent is not altered based on multifocal or multicentric disease compared to patients presenting with a single tumor.
Though previous researchers have analyzed data on patients with this type of breast cancer, “there is not a strong consensus on whether or not having multifocal or multicentric breast cancer leads to higher recurrence rates,” says Tiffany Tam, MD, an attending physician in the Radiation Oncology Department at Fox Chase Cancer Center, who will present new findings about this on October 30 at the American Society for Radiation Oncology’s 54th Annual Meeting.
Tam led a team of Fox Chase physicians in a retrospective study designed to investigate for possible differences in outcomes. They found no statistically significant difference in overall survival or distant recurrence, where the cancer spreads to other organs or tissues. However, local recurrence—having cancer return to the same area from which it was surgically removed—occurred more than 2.5 times more often among patients with multifocal/multicentric disease, compared to patients with a single tumor.
Tam and her colleagues analyzed the medical records of 112 women who were treated for multifocal or multicentric breast cancer at Fox Chase between 1983 and 2010. They compared outcomes data from those patients with data from 263 women treated for unifocal disease during the same period. Patients from the two groups were matched by age, gender, and stage at diagnosis. The researchers incorporated data on hormone-receptor status, type of surgery, age, grade, stage, and other therapies into their analyses. Males and patients with ductal carcinoma in situ (DCIS), inflammatory breast cancer, or metastatic disease were all excluded from the study.
Overall survival rates and rates of distant recurrence were roughly equal between both groups. When the researchers accounted for all the variables, they found that multifocal or multicentric breast cancer patients were diagnosed with local recurrences about 2.6 times as often as patients with unifocal disease.
Tam says she was motivated to do the study after treating patients diagnosed with multifocal or multicentric disease. “For those patients who do not have any other indications for post-mastectomy radiation, I wondered whether or not multifocal or multicentric disease should be considered in the decision to offer radiation,” she says.
The new study won't change clinical practice guidelines, Tam says, but it suggests that the number of tumors found in the breast perhaps should be considered—along with other risk factors when considering radiation therapy.
“Even though this study suggests having multifocal or multicentric disease leads to increase local recurrence, we cannot draw definite conclusions, as this is just a single institutional small retrospective study. It's an additional factor that oncologists can consider,” Tam adds. It's not clear whether or not patients with this type of disease have a more aggressive form of cancer or if they have some other risk factor that makes them more susceptible to developing multiple tumors.
Those patients may benefit from radiation therapy following mastectomy, for example, to reduce the likelihood of local recurrence, though larger studies are needed to weigh the possible benefits against possible harms.
Tam's coauthors include Penny Anderson, Tianyu Li, Lori Goldstein, Richard Bleicher, Marcia Boraas, Elin Sigurdson, Paula Ryan, and Shelly Hayes from Fox Chase.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).